12 / 48 Week Pivotal PFT vs PBO in COPD I
Public ClinicalTrials.gov record NCT00782210. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 mcg [2 Actuations of 2.5 mcg] and 10 mcg [2 Actuations of 5 mcg]) Delivered by the Respimat® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This primary objective of this study is to compare two doses of BI 1744 CL inhalation solution delivered by the Respimat® inhaler once daily to placebo in patients with chronic obstructive pulmonary disease (COPD). The safety of BI 1744 CL inhalation solution delivered through the Respimat inhaler will also be compared to placebo.
Study identification
- NCT ID
- NCT00782210
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 625 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2008 (Type not available)
- Primary completion
- Sep 2010 (Actual)
- Completion
- Not listed
- Last update posted
- Jun 9, 2014
Started 2008
United States locations
- U.S. sites
- 21
- U.S. states
- 15
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1222.11.1122 Boehringer Ingelheim Investigational Site | Jasper | Alabama | — | — |
| 1222.11.1116 Boehringer Ingelheim Investigational Site | Berkeley | California | — | — |
| 1222.11.1121 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1222.11.1111 Boehringer Ingelheim Investigational Site | Fort Collins | Colorado | — | — |
| 1222.11.1117 Boehringer Ingelheim Investigational Site | Stamford | Connecticut | — | — |
| 1222.11.1110 Boehringer Ingelheim Investigational Site | DeLand | Florida | — | — |
| 1222.11.1106 Boehringer Ingelheim Investigational Site | Coeur d'Alene | Idaho | — | — |
| 1222.11.1108 Boehringer Ingelheim Investigational Site | Evansville | Indiana | — | — |
| 1222.11.1109 Boehringer Ingelheim Investigational Site | Bowling Green | Kentucky | — | — |
| 1222.11.1113 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1222.11.1115 Boehringer Ingelheim Investigational Site | Larchmont | New York | — | — |
| 1222.11.1120 Boehringer Ingelheim Investigational Site | Toledo | Ohio | — | — |
| 1222.11.1105 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 1222.11.1112 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 1222.11.1119 Boehringer Ingelheim Investigational Site | Greer | South Carolina | — | — |
| 1222.11.1102 Boehringer Ingelheim Investigational Site | Union | South Carolina | — | — |
| 1222.11.1124 Boehringer Ingelheim Investigational Site | Killeen | Texas | — | — |
| 1222.11.1101 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 1222.11.1103 Boehringer Ingelheim Investigational Site | Spokane | Washington | — | — |
| 1222.11.1114 Boehringer Ingelheim Investigational Site | Spokane | Washington | — | — |
| 1222.11.1123 Boehringer Ingelheim Investigational Site | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00782210, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 9, 2014 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00782210 live on ClinicalTrials.gov.